COVIDRIVE

A public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe 

What is COVIDRIVE?

COVIDRIVE is a not-for-profit public-private partnership launched in June 2021 to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. To tackle the COVID-19 public health crisis, the European Medicines Agency (EMA) has recommended to make use of existing efforts and encourage a common approach to assess COVID-19 vaccines in real life settings.

COVIDRIVE is performing brand-specific studies through a multi-stakeholder’s public-private European collaborative platform. Our first COVID-19 vaccine effectiveness study started in September 2021.
COVIDRIVE is leveraging an existing vaccine effectiveness platform (DRIVE) which provides yearly brand-specific influenza vaccine effectiveness (IVE) estimates to the EMA.

COVIDRIVE consortium is open to new partners (public health institutes, pharmaceutical companies, small-medium enterprises, academia…) and new study sites to be part of our European-wide network.

VISION AND MISSION

JOINING FORCES TOWARDS A BETTER UNDERSTANDING OF VACCINES AND PREVENTION OF INFECTIOUS DISEASES

To jointly develop methodological and technical resources to undertake CVE vaccine studies in Europe

To set up a research network of Study Contributors across Europe and be able to conduct multi-centre infectious disease and vaccine studies representative of the continent

To leverage established public health capacities and optimize Health Care Practitioner resources in data collection

To build a sustainable partnership by establishing and maintaining a rich scientific community, central data sharing & analysis platform, supporting study documents and regulatory pathway processes

Scope

The partnership intends to conduct multiple COVID-19 vaccine effectiveness (CVE) studies which fall under the following scope:
  • overall and/or vaccine type and/or brand-specific,
  • severe, mild and/or asymptomatic COVID-19 disease outcomes,
  • hospital and/or primary care setting(s),
  • population(s) targeted by the vaccination and/or population(s) of special interest,
  • mid-term and/or long-term CVE,
  • CVE by genetic variants,
  • CVE by time since vaccination and/or by calendar time, and
  • CVE by disease level of severity.

    • PARTNERS

    NON INDUSTRY PARTNERS
    Fisabio Completo_inglés
    P95_LOGO_RGB

    FISABIO (Spain)

    Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

    P95 (Belgium)

    Excellence in pharmacovigilance and Epidemiology 

    VACCINE COMPANIES

    AstraZeneca
    (United Kingdom)

    Bavarian Nordic
    (Denmark)

    GlaxoSmith Kline
    (Belgium)

    Janssen
    (Belgium)

    Valneva
    (France)

    Novavax
    (United States)